

Peter van den Elzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9064211/publications.pdf>

Version: 2024-02-01

24
papers

1,102
citations

566801

15
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

1997
citing authors

#	ARTICLE	IF	CITATIONS
1	Apolipoprotein-mediated pathways of lipid antigen presentation. <i>Nature</i> , 2005, 437, 906-910.	13.7	323
2	Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. <i>Journal of Clinical Investigation</i> , 2011, 121, 57-69.	3.9	137
3	Conserved and Heterogeneous Lipid Antigen Specificities of CD1d-Restricted NKT Cell Receptors. <i>Journal of Immunology</i> , 2006, 176, 3625-3634.	0.4	91
4	Innate immune control of EBV-infected B cells by invariant natural killer T cells. <i>Blood</i> , 2013, 122, 2600-2608.	0.6	80
5	Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells. <i>Blood</i> , 2009, 114, 2411-2416.	0.6	72
6	CD1d and CD1c Expression in Human B Cells Is Regulated by Activation and Retinoic Acid Receptor Signaling. <i>Journal of Immunology</i> , 2011, 186, 5261-5272.	0.4	52
7	Self-reactive T cells and Degeneracy of T Cell Recognition: Evolving Concepts from Sequence Homology to Shape Mimicry and TCR Flexibility. <i>Journal of Autoimmunity</i> , 2001, 16, 201-209.	3.0	51
8	A public T cell clonotype within a heterogeneous autoreactive repertoire is dominant in driving EAE. <i>Journal of Clinical Investigation</i> , 2007, 117, 2176-2185.	3.9	48
9	Molecular Characterization of the T Cell Repertoire Using Immuno-scope Analysis and its Possible Implementation in Clinical Practice. <i>Current Molecular Medicine</i> , 2001, 1, 297-304.	0.6	34
10	CD1 assembly and the formation of CD1 antigen complexes. <i>Current Opinion in Immunology</i> , 2005, 17, 88-94.	2.4	32
11	Autoreactive T cells can be protected from tolerance induction through competition by flanking determinants for access to class II MHC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5342-5347.	3.3	31
12	Differential Expression of T-bet, a T-box Transcription Factor Required for Th1 T-Cell Development, in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2003, 120, 866-873.	0.4	28
13	Administration of PLP139 ¹⁵¹ Primes T Cells Distinct from Those Spontaneously Responsive In Vitro to This Antigen. <i>Journal of Immunology</i> , 2008, 180, 6611-6622.	0.4	19
14	Autoreactivity to Sulfatide by Human Invariant NKT Cells. <i>Journal of Immunology</i> , 2017, 199, 97-106.	0.4	19
15	Activation of invariant natural killer T cells stimulated with microbial α -mannosyl glycolipids. <i>Scientific Reports</i> , 2017, 7, 9703.	1.6	16
16	NKT Cells Are Required for Complete Freund's Adjuvant-Mediated Protection from Autoimmune Diabetes. <i>Journal of Immunology</i> , 2011, 187, 2898-2904.	0.4	15
17	Limited clonality in autoimmunity: drivers and regulators. <i>Autoimmunity Reviews</i> , 2004, 3, 524-529.	2.5	14
18	Residual public repertoires to self. <i>Journal of Neuroimmunology</i> , 2000, 107, 233-239.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Seven Surprises in the TCR-Centred Regulation of Immune Responsiveness in an Autoimmune System. Novartis Foundation Symposium, 2008, 252, 165-176.	1.2	9
20	Characterization of Adaptive-like $\gamma\delta$ T Cells in Ugandan Infants during Primary Cytomegalovirus Infection. <i>Viruses</i> , 2021, 13, 1987.	1.5	6
21	Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis. <i>Immunology</i> , 2010, 130, 288-295.	2.0	5
22	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. <i>Cancers</i> , 2020, 12, 169.	1.7	5
23	Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 539-542.	3.3	4
24	Acidification-dependent Activation of CD1d-restricted Natural Killer T Cells is Intact in Cystic Fibrosis. <i>Clinical Immunology</i> , 2010, 135, S110-S111.	1.4	0